Joris Kleintjens

  • Citations Per Year
Learn More
BACKGROUND Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial fibrillation (AF). Recently, rivaroxaban, a novel oral anticoagulant (NOAC) which offers some distinct advantages over warfarin, the standard of care in a world without NOACs,(More)
OBJECTIVES Studies on medical resource utilization (MRU) and related costs are important for evaluating the potential patient management and cost-effectiveness implications of antiviral treatments for hepatitis C virus (HCV) infection. The objectives of this study were (i) to compare the MRU and related costs for two treatment approaches; (ii) to identify(More)
OBJECTIVE Limited evidence is available on predictors of medical resource utilization (MRU) and related direct costs, especially in treatment-experienced patients infected with genotype 1 hepatitis C virus (HCV). This study aimed at investigating patient and treatment characteristics that predict MRU and related non-drug costs in treatment-experienced(More)
PIN66 LoNg-Term ouTcomes of LedIPasvIr/sofosbuvIr (Ldv/ sof) for The TreaTmeNT of chroNIc hePaTITIs c INfecTed (hcv) geNoTyPe 1 PaTIeNTs IN The uK Guerra I.1, Marie L.2, Cure S.1 1OptumInsight, Uxbridge, UK, 2OptumInsight, Nanterre, France Objectives: Sofosbuvir (SOF) is a uridine analogue polymerase inhibitor. Ledipasvir (LDV) is an inhibitor of the(More)
This study describes epidemiological trends for acute rotavirus gastroenteritis (RVGE) in Belgium in children aged ⩽5 years during the period June 2007 to May 2014 after the introduction of routine rotavirus (RV) vaccination. This period encompassed the switch from lyophilized to the liquid formulation of Rotarix™ (GlaxoSmithKline, Belgium) in August 2011.(More)
  • 1